Format

Send to

Choose Destination

See 1 citation:

Exp Cell Res. 2015 Sep 10;337(1):68-75. doi: 10.1016/j.yexcr.2015.07.018. Epub 2015 Jul 21.

Effects of cilengitide in osteoclast maturation and behavior.

Author information

1
Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria.
2
Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
3
Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria. Electronic address: gerald.prager@meduniwien.ac.at.

Abstract

Bone metastasis is a common burden in many types of cancer and has a severe impact on the quality of life in patients. Hence, specific therapeutic strategies inhibiting tumor induced osteolysis are urgently needed. In this study, we aimed to interfere with integrin adhesion receptors, which are central players of the bone resorption process. For this purpose, we used cilengitide, a cyclic RGD peptide, which blocks integrin αVβ3 and αVβ5-ligand binding. Our results revealed that cilengitide blocked osteoclast maturation in a dose-dependent manner. In detail, pre-osteoclasts treated with cilengitide exhibited reduced cell spreading, cell migration and cell adhesion on RGD-containing matrix proteins, which are ligands of integrin αV. The activation of the most upstream signal transduction molecules of the integrin receptor-initiated pathway, FAK and c-Src, were consistently blocked by cilengitide. First evidence suggests that cilengitide might interfere with metastatic bone disease in vivo and this study describes a potential underlying mechanism of the inhibitory effect of cilengitide on αV-integrin expressing pre-osteoclasts by blocking integrin ligand binding and interfering with osteoclast maturation and cell behavior. In conclusion, our findings suggest that cilengitide, which interferes with αV-integrins on osteoclasts, may represent a novel therapeutic strategy in the treatment of malignant bone disease.

KEYWORDS:

Integrin; Metastatic bone disease; Osteoclast; RGD-peptide

PMID:
26209605
DOI:
10.1016/j.yexcr.2015.07.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center